Hyperhomocysteinemia, C677T MTHFR Polymorphism And Ischemic Stroke In Tunisian Patients

##plugins.themes.academic_pro.article.sidebar##

Published Aug 31, 2010
Download
pdf
Vol. 88 No. 9 (2010): Issue Sep 2010

##plugins.themes.academic_pro.article.main##

Olfa Ben Salem-Berrabah
Nejiba Fekih-Mrissa
Mabrouka El Oudi
Sami Layouni
Ines Louati
Zied Aouni
Chakib Mazigh
Brahim N'siri
Abdelhamid Ben Hamida
Salem Machghoul
Ridha Mrissa
Nasreddine Gritli

Abstract

Background: Hyperhomocysteinaemia has been identified as a strong risk factor for ischemic stroke (IS). A point mutation in methylene tetrahydrofolate reductase (MTHFR C677T) has been associated with increased plasma homocysteine (Hcy) levels.
Aim: This preliminary study aimed to investigate whether hyperhomocysteinaemia and/or MTHFR C677T mutation are associated with ischemic stroke.
Methodes: A case-control study including 50 consecutive patients with confirmed IS and 97 controls was performed. Fasting plasma homocysteine levels, MTHFR C677T genotypes were assessed. Other factors such as hypertension, obesity, dyslipidemia, diabetes mellitus, recurrent stroke tobacco and alcohol were investigated.
Results: Mean plasma homocysteine levels were significantly higher in IS patients than in controls (15.83±10.60) μmol/L vs 13.78±6.29 μmol/L, p=0.04), while no association of MTHFR C677T variant was observed even with homocysteine. The risk to develop ischemic stroke in hyperhomocysteinemic subjects was 2.4 times more than in subjects with normal Hcy levels (OR= 2.4; 95% CI: 1.13-5.06; p<0.05).
Conclusion: Our findings suggest that high levels of homocysteine but not MTHFR C677T polymorphism represent risk factors for arterial ischemic stroke in Tunisian subjects.

Keywords:

Homocysteine levels, MTHFR C677T polymorphism, risk factor, Ischemic Stroke, Tunisia

##plugins.themes.academic_pro.article.details##

References

  1. Strong K, Mathers C, Bonita R. Preventing stroke: Saving lives around the world. Lancet Neurol 2007;6:182-7.
  2. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global burden of disease study. Lancet 1997;349:1269- 1276.
  3. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325: 1202-6.
  4. Lee R, Frenkel EP. Hyperhomocysteinemia and thrombosis. Hematol Oncol Clin North Am 2003;17:85-102.
  5. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998 158:2101-6.
  6. Moller J, Nielsen GM, Tvedegaard KC, Andersen NT, Jorgensen PE. A meta-analysis of cerebrovascular disease and hyperhomocysteinaemia. Scand J Clin Lab Invest 2000;60:491-9.
  7. Matthews RG, Sheppard C, Goulding C. Methylenetetrahydrofolate reductase and methionine synthase: Biochemistry and molecular biology. Eur J Pediatr 1998;157 (Suppl 2):S54-9.
  8. Engbersen AM, Franken DG, Boers GH, Stevens EM, Trijbels FJ, Blom HJ. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 1995;56:142-50.
  9. Soriente L, Coppola A, Madonna P, Cerbone AM, Di Minno G, Orefice G et al. Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of earlyonset ischemic stroke. Stroke 1998;29:869-71.
  10. Pezzini A, Del Zotto E, Archetti S, Negrini R, Bani P, Albertini A et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke 2002;33:664-9.
  11. Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Lang T et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. J Lab Clin Med 1999;133:575-82.
  12. Tantirittisak T, Sura T, Moleerergpoom W, Hanchaipiboolkul S. Plasma homocysteine and ischemic stroke patients in Thailand. J Med Assoc Thai 2007;90:1183-7.
  13. Biswas A, Ranjan R, Meena A, Akhter MS, Yadav BK, Munisamy M et al. Homocystine levels, polymorphisms and the risk of ischemic stroke in young Asian Indians. J Stroke Cerebrovasc Dis 2009;18:103-10.
  14. Moe KT, Woon FP, De Silva DA, Wong P, Koh TH, Kingwell B et al. Association of acute ischemic stroke with the MTHFR C677T polymorphism but not with NOS3 gene polymorphisms in a Singapore population. Eur J Neurol 2008;15:1309-14.
  15. Ntaios G, Savopoulos C, Hatzitolios A, Ekonomou I, Destanis E, Chryssogonidis I, et al. Homocysteine and carotid intima-media thickness in ischemic stroke patients are not correlated. Neuropsychiatr Dis Treat 2008;4:477-9.
  16. Sabino A, Fernandes AP, Lima LM, Ribeiro DD, Sousa MO, de Castro Santos ME et al. Polymorphism in the methylenetetrahydrofolate reductase (C677T) gene and homocysteine levels: a comparison in Brazilian patients with coronary arterial disease, ischemic stroke and peripheral arterial obstructive disease. J Thromb Thrombolysis 2009;27:82-7.
  17. Kelly PJ, Rosand J, Kistler JP, Shih VE, Silveira S, Plomaritoglou A et al. Homocysteine, MTHFR 677C-->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59: 529-36.
  18. Uçar F, Sönmez M, Ovali E, Ozmenoglu M, Karti SS, Yilmaz M et al. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. Am J Hematol 2004; 76:40-3.
  19. McColl MD, Chalmers EA, Thomas A, Sproul A, Healey C, Rafferty I et al. Factor V Leiden, prothrombin 20210G-->A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999;81:690-4.
  20. Lopaciuk S, Bykowska K, Kwiecinski H, Mickielewicz A, Czlonkowska A et al. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Hemost 2001;7:346-50.
  21. Marie SK, Shinjo SK, Oba-Shinjo SM, da Silva R, Barbosa KC, Yamamoto F et al. Methylenetetrahydrofolate reductase gene polymorphism is not related to the risk of ischemic cerebrovascular disease in a Brazilian population. Clinics (Sao Paulo) 2007;62:295-300.
  22. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001;47:255-62.
  23. Harmon DL, Doyle RM, Meleady R, Doyle M, Shields DC, Barry R et al. Genetic analysis of the thermolabile variant of 5,10 methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 1999;19:208-11.
  24. Li CM, Zhang C, Lu XL, Feng HY, Su QX, Zeng Y et al. Relationship between methylenetrahydrofolate reductase gene and ischemic stroke. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2006;18:264-7.
  25. Khan NI, Naz L, Mushtaq S, Rukh L, Ali S, Hussain Z. Ischemic stroke: prevalence of modifiable risk factors in male and female patients in Pakistan. Pak J Pharm Sci 2009;22:62-7.
  26. Galimanis A, Mono ML, Arnold M, Nedeltchev K, Mattle HP. Lifestyle and stroke risk: a review. Curr Opin Neurol 2009;22:60-8.
  27. He Y, Lam TH, Jiang B, Wang J, Sai X, Fan L et al. Passive smoking and risk of peripheral arterial disease and ischemic stroke in Chinese women who never smoked. Circulation 2008; 118:1535-40.
  28. Park JW, Lee SY, Kim SY, Choe H, Jee SH. BMI and stroke risk in Korean women. Obesity (Silver Spring) 2008;16:396-401.
  29. Gállego J, Martínez Vila E, Muñoz R. Patients at high risk for ischemic stroke: identification and actions. Cerebrovasc Dis 2007;24 (Suppl 1):49-63.
  30. Mukamal KJ, Ascherio A, Mittleman MA, Conigrave KM, Camargo CA, Kawachi I et al. Alcohol and risk for ischemic stroke in men: the role of drinking patterns and usual beverage. Ann Intern Med 2005;142:11-9.